Update:
Following publication, the FDA issued an official press release confirming that six on！ PLUS nicotine pouch products had received Marketing Granted Orders (MGO) through the PMTA pathway. The announcement states that the authorizations were completed under the agency’s nicotine pouch review pilot program and were finalized in record time. A screenshot of the FDA press release page is included below.
Key Points：
- The FDA has added on！ Plus nicotine pouches to its list of PMTA-authorized products.
- on！ Plus is the second nicotine pouch brand to receive a Marketing Granted Order (MGO), after ZYN.
- The authorization was disclosed through an update to the FDA’s website; no separate press release had been issued as of publication.
2Firsts ，December 19, 2025，The U.S. Food and Drug Administration (FDA) has updated its online list of nicotine pouch products authorized by the agency, disclosing that on！ Plus nicotine pouches have received Marketing Granted Orders (MGO) via the Premarket Tobacco Product Application (PMTA) pathway—allowing the products to be legally marketed in the United States.
The update makes on！ Plus the second nicotine pouch brand authorized via PMTA, alongside Swedish Match’s ZYN.
As of publication, the FDA had not issued a separate press release on the decision, disclosing the authorization instead through an update to its list of authorized nicotine pouch products.
What’s Authorized (FDA List)
According to the FDA’s “Nicotine Pouch Products Authorized by the FDA” page, the authorized on！ Plus SKUs include:
on！ PLUS nicotine pouches 6 mg Mint
on！ PLUS nicotine pouches 9 mg Mint
on！ PLUS nicotine pouches 6 mg Tobacco
on！ PLUS nicotine pouches 9 mg Tobacco
on！ PLUS nicotine pouches 6 mg Wintergreen
on！ PLUS nicotine pouches 9 mg Wintergreen
These additions appear on the same FDA-authorized list that includes multiple ZYN nicotine pouch products previously granted marketing orders through PMTA.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
